Innovative drug developers presented to over 20 investors at the Munich Start-Up Center
The 6th Munich Life Science Pitch Day was organized in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim and the IZB
Martinsried, September 1. October, 2021 – Once again the Munich Life Science Pitch Day on the September 30, 2001 in Munich was a total success for both the project teams and the more than 20 investors. This event takes place every year in cooperation with High-Tech-Gründerfonds (HTGF), Bayer AG, Boehringer Ingelheim and the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried near Munich. 35 project teams from the life science sector had applied. Ten start-ups had the opportunity to present their innovative drug development projects to renowned venture capital companies. Dr. Martin Pfister, principal of HTGF moderated the event and introduced the HTGF. Dr. Peter Hanns Zobel, Managing Director of the IZB, gave a glimps into the dynamic Start-Up Center IZB. Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership, Bayer AG explained what kinds of cooperation models exist at Bayer AG. The participants followed the fireside chat with Dr. Martin Pfister and Dr. Ingmar Hoerr, founder of CureVac AG with great interest.
The following investors attended this event: Abbvie, Apollo Health Ventures, Bayer, Bayern Capital, BioMed Partners, bmp Ventures, Boehringer Ingelheim, Coparion, Forbion Capital Partners, Hadean Ventures, HTGF, KURMA Partners, Long VC, LSP, mbc, Maximon, Medi Ventures, Occident Group, Seventure, TVM Capital, Vantage Value, Vesalius Biocapital and Wellington Partners.
“We are pleased to be able to give start-ups the opportunity every year to present before top-class venture capital companies in order to establish contacts with investors at an early stage. I would very much like to thank our long-term partners, who leave with an extremely positive impression of the Munich start-up scene,” explains Dr. Peter Hanns Zobel, Managing Director of the IZB.
“With the Munich Life Science Pitch Day we have established an outstanding event together with the IZB, Bayer AG and Boehringer Ingelheim, which has taken place for the sixth time in Munich. This is where partnerships emerge from which the life science start-ups and all participating investors benefit. At the same time, all participants gain valuable insights into the innovative strength of young start-ups. This is real added value for everyone involved. We are already looking forward to the next Pitch Day,” according to Dr. Caroline Fichtner, Principal of HTF.
“The Life Science Pitch Day offers the best possible framework for targeted networking with established investors. The ten participating life science start-ups impressed us with their innovative ideas. It was also a pleasure for me to round off the event in an interesting conversation with our guest Ingmar Hoerr, founder of CureVac,” says Dr. Martin Pfister, Principal of HTGF.
“A central aspect of a pitch event is networking. The founders have the chance to make important contacts with potential investors and partners. And it is precisely this exchange that is made possible at the Life Science Pitch Day in Munich. I was very impressed by the quality of the young start-ups’ research. It was great to follow the lively exchange and get to know the start-ups,” explains Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership, Bayer AG.
“At the Life Science Pitch Day, interesting partnerships and synergies can emerge between investor:ing and the innovative founder:ing scene. Events like these make a valuable contribution to promoting innovation and opening up new horizons for completely new therapeutic approaches for patients. The quality of the founding teams and the forward-looking solutions of the pitching start-ups are a real enrichment for the life science sector,” says Alexander Ehlgen, Boehringer Ingelheim Venture Fund.
The investors were enthusiastic about the innovative drug developers. The following project teams presented at the “6th Munich Life Science Pitch Day”:
- Dimericon, Ulrich Kessler: Dimericon, Ulrich Kessler: Fighting cancer – A novel therapeutic modality conquering the plasticity conundrum in IDP-targeted oncology drug discovery
- Fundamental Pharma, Thomas Schulze: Next generation brain drugs acting as molecular spacers to halt neurodegeneration
- FUSIX Biotech, Jennifer Altomonte: A TUM spin-off developing a “best-in-class” oncolytic virus platform to treat solid tumors
- Galimedix, Alexander Gebauer: Breakthrough therapy in Alzheimer´s disease:
Small molecule GAL-201 for cognitive improvement and neuroprotection
- Intellexon, Christoph Winterhalter: Intellexon uncovered new embryo-fetal HLAs as unique tumor targets
- Invasight, Karthiga Santhana Kumar: Developing potent and safe first-in-class, protein-protein interaction inhibitors against invasive cancers
- OPSYON, Nadja Fenn: OPSYON’s vision and mission is to combine direct cancer cell targeting with the benefits of immune checkpoint inhibition in one molecule to maximize anti-cancer efficacy while minimizing unwanted side effects.
- RecTec, Anne-Kristin Heninger: It is our vision to establish designer recombinases as the leading technology for safe and precise genome surgery to cure genetic diseases.
- Riana Therapeutics, Anna Orlova: We develop novel first-in-class treatment options against cancer
- Sirana Pharma, Hermann-Josef Kaiser: Restoring musculoskeletal health
Investors of the 6th Munich Life Science Pitch Day 2021 (v.l.n.r.): Rajput Ashish, LongeVC and Maximon; Cédric Barra, Occident Group; Philipp Kopp, mbc; Catello Somma, TVM; Daniel Parara, Kurma Partners; Ivan Morace, Medi Ventures; Dimitriy Hristodorov, Forbion Captial Partners; Mario Richter, Abbvie; Kilian Sörgel, Vantage Value; Jakob Lilienweis, HTGF; Dr. John E.Butler-Ransohoff, Bayer AG; Sascha Berger, TVM; Laura Pedroza, HTGF; Christian Schneider, Vesalius Biocapital; Markus Dietrich, Hadean Ventures, Dr. Marianne Mertens, Apollo Health Ventures; Karl Nägler, Wellington Partners; Joachim Vogt, Abbvie; Thomas Möller, BioMed Partners; Andreas Huber, Bayern Kapital; Dr. Fei Tian, Vesalius Biocapital; Philipp Bräuer LSP; Johannes Fischer, Wellington Partners; Aagam Shah, Occident Group (f.l.t.r.):
About Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB mbH, founded in 1995, is the operating company of the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently located on 26,000 m2 of land. Here, work focuses on the development of drugs against the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is their close proximity to top-level research at both the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt Chemistry College, the two kindergartens Bio Kids and Bio Kids2, as well as the two restaurants SEVEN AND MORE and Café Freshmaker are also location factors that are highly appreciated by the company founders. Successful companies that have emerged from the IZB include Medigene AG, MorphoSys AG, Micromet GmbH (today Amgen AG), Octopharma GmbH, Corimmun (today Janssen-Cilag), Rigontec GmbH (today MSD), ibidi GmbH, Coriolis GmbH and Immunic Therapeutics. More information at www.izb-online.de
Press contact and image requests:
Susanne Simon, Head of Public Relations
Fördergesellschaft IZB mbH
Am Klopferspitz 19
D-82152 Planegg Martinsried
Phone: +49 (0)89/55 279 48-17,
About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 140 companies.
Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG. www.htgf.de/en
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 – 82300 – email@example.com